Heather J. Allen, MD

Dupuy DE, Liu D, Hartfeil D, et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter trial: American College of Radiology Imaging Network 6661. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 9101).

El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 9043).

Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22:300-306.

Kohli S, Fisher G, Tra Y, Wesnes K, Morrow GR. The cognitive effects of modafinil in breast cancer survivors: a randomized clinical trial. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. June 20 2006;25(suppl 18): (abstract 9004).

Thompson SL, Bardia A, Tan A, et al. Levetiracetam for the treatment of hot flashes: a pilot study. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 9116).

Joanne L. Blum, MD, PhD

Burnell MJ, Levine MN, Chapman JA, et al. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 550).

Cuppone F, Bria E, Giannarelli D, et al. Meta-analysis of adjuvant trastuzumab for early breast cancer: cardiotoxicity and brain metastases incidence. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 543).

Goldstein LJ, Gray R, Childs BH, et al. Prognostic utility of 21-gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of Intergroup Trial E2197. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 526).

Kaufman PA, Broadwater G, Lezon-Geyda K, et al. Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1009).

Lo SS, Norton J, Mumby PB, et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 577).

Loesch DM, Greco F, O'Shaughnessy J, et al. A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 517).

Paik S, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 511).

Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 512).

Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)?paclitaxel (T) vs. AC?T with trastuzumab (H). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA513).

Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 516).

Michael A. Danso, MD

Alba E, Ruiz-Borrego M, Martín M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1007).

Baselga J, Bianni L, Llombart A, et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat. 2005;94(Suppl 1):S31 (abstract 305).

Blum JL, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1034).

Conte P, Thomas E, Martin M, Kliovsky J, Tabernero J. J Clin Oncol. 2006 ASCO Ann Meet Proc. 20 June 2006;25(suppl 18): (abstract 10505).

Di Leo A, Gomez H, Aziz Z, et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1011).

Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol, 2006 ASCO Ann Meet Proc Part I. 20 June 2006;25(suppl 18): (abstract LBA516).

Geyer CE, Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1035).

Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A, Hawkins, MJ. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1032).

Guan Z, Feng F, Li QL, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1038).

Jones SF, Burris HA, Yardley DA, et al. Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. Proc SABCS. 2004: (abstract 1069).

Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086-1095.

Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1012).

Low JA, Wedman SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-2734.

Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first-line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA1008).

Roché H, Yelle L, Peck R. Efficacy results of a phase II study of ixabepilone in patients with metastatic breast cancer previously treated with an anthracycline. International Union Against Cancer World Cancer Congress. 8-12 July 2006: (abstract 96-3).

Thomas E, Perez EA, Mukhopadhyay P, et al. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol. 2006 ASCO Ann Meet Proc. 20 June 2006;24 (suppl18): (abstract 660).

Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 1006).

Verrill MW, Lee J, Cameron DA, Agrawal R, et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA1005).

Nicholas J. DiBella, MD

Barlogie B, Anaissie E, Shaughnessy JD Jr, et al. Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8020).

Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817-3823.

Federico M, Bellei M, Pro B, et al. Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8008).

Harousseau JL, Nagler A, Sonneveld P, et al. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8002).

Hulin C, Virion J, Leleu X, et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8001).

Ladetto M, Corradini P, Vallet, S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano. Trapianto Midollo Osseo (GITMO). Blood. 2002;100:1559-1565.

Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8006).

Ladetto M, Vallet S, Benedetti F, et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia. 2006;20:1840-1847.

Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667-2674.

Mounier N, Ribrag V, Haioun C, et al. Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: a randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8010).

Rajkumar SV, et al. Phase III trial of lenalidomide plus high-dose dex versus lenalidomide plus low-dose dex in newly diagnosed MM (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA8025).

Sebban C, Mounier N, Brousse N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2006;108:2540-2544.

Sonneveld P, Hajek R, Nagler A, et al. Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8023).

Vose J, Bierman P, Bociek G, Loberiza F, Enke C, Hankins J, Armitage J. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 8013).

Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase I Trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:461-467.

Thomas E. Hutson, DO, PharmD

Berthold DR, Pond G, DeWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5005).

Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT: Results of the randomized EORTC Phase III trial 22961. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5014).

Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5023).

Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.

Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 3).

Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5015).

Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5024).

Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5019).

Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 5025).

A. David McCollum, MD

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. NEJM. 2004;350:2343-2351.

Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 4030).

de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 4007).

Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA1).

Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA5).

Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 4028).

Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 4000).

Eric Nadler, MD

Hanna, N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038-2043.

Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7512).

Hermes A, Bergman B, Bremnes R, et al. A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7523).

Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract LBA7514).

Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. NEJM. 2002;346:85-91.

Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7535).

Slotman B, Faivre-Finn C, Kramer G, et al. A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993-22993). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 4).

Robert M. Rifkin, MD, FACP

Agura ED, Berryman R, Cooper B, et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7064).

Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clinc Oncol. 2003;21:4642-4649.

Garcia-Manero G, Kantarjian HM, Sanchez-Gonzales B, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.

Issa J, Saba HI, Garcia-Manero G, Shan J, Kantarjian HM. Decitabine in older patients with acute myelogenous leukemia (AML). J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7021).

Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.

Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.

Powell BL, Moser B, Stock W, et al. Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. Blood, ASH Annual Meeting Abstracts. 2006;108(26): (abstract 566).

Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 2).

Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia patients with outpatient azacitidine. Cancer. 2006;107:1839-1843.

Tam CS, O’Brien S, Wierda W, Lerner S, Kantarjian H, Keating MJ, et al. Seventy percent of complete responders remain in continuous remission: five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL. J Clin Oncol, 2007 ASCO Ann Meet Proc Part I. 20 June 2007;25(suppl 18): (abstract 7008).

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.